Long-term follow-up of combination therapy with pembrolizumab and anlotinib in thoracic SMARCA4-deficient undifferentiated tumor: a case report and molecular features

Long-term follow-up of combination therapy with pembrolizumab and anlotinib in thoracic SMARCA4-deficient undifferentiated tumor: a case report and molecular features

Thoracic SMARCA4-deficient undifferentiated tumors (SMARCA4-UTs), recently recognized as a rare malignancy described in the 5th edition of the World Health Organization Classification of Tumors, are characterized by an inactivating mutation in SMARCA4, most commonly found in the mediastinum of male...

Full description

Saved in:
Bibliographic Details
Main Authors: Ting Duan, Mingxin Xu, Haibo Zhang, Shengchang Wu, Haochu Wang, Zhenying Guo
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-12-01
Series:Frontiers in Oncology
Subjects:
lung cancer
SMARCA4-UT
immune checkpoint inhibitors
anti-angiogenic agent
prognosis
genen mutation
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1453895/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items